Jeena Sikho Lifecare: June quarter profit up 28%, but margin slipped to 41%. What to check before you buy
Jeena Sikho Lifecare's profit for the June 2026 quarter rose 28% to ₹65.7 crore, but about ₹7 crore of that was a one-time gain and the operating margin slipped to 41%. In the year to March 2026 it earned ₹222 crore, almost three times the year before. The stock has still fallen from ₹840 to about ₹481. This article shows what is behind the fall and what to check before you buy.
Jeena Sikho Lifecare (NSE: JSLL) - Share price: ₹480.8 (1 October 2026 close, the last trading day; 2 October was a market holiday) - Market cap: ₹5,976 crore - P/E on the last twelve months' profit (TTM): 25.3 (listed hospital chains: Shalby 36.7, Rainbow Children's 45.4, Max Healthcare 61.2, KIMS 148. No listed Ayurveda hospital chain exists to compare with.) - Price to book value: about 12.8 (the book value is ₹37.6 per share) - ROCE: 64.4%, return on equity: 61.4%. Both show how much profit the company makes from the money invested in it. - Dividend: ₹4.50 per share for FY26 (yield 0.94%) - 52-week range: ₹474 to ₹840. The price is 43% below the high and 1.5% above the low.
What the company does
Jeena Sikho started in 2009, when its promoter (founding owner) Manish Grover set up the God Grace Foundation and later the "Divya Upchar" brand. The company was incorporated in 2017. It listed on NSE Emerge, the small-company platform, in April 2022 (issue size ₹55.5 crore). It moved to the NSE and BSE main boards on 11 August 2025. This is not a recent IPO, so this article looks at the business and not at the issue.
It runs about 120 Ayurveda hospitals, clinics and day-care centres in 23 states. It has two businesses: - Services (47% of revenue in Q1 FY27). Panchakarma, a classical Ayurveda therapy, in hospital stays and day-care visits. Patients come through free health camps and free consultations. - Products (53%). Ayurveda medicines and health products, sold mainly on its own website. A new sales deal with Entero Healthcare puts them in medical stores.
Key numbers for the June 2026 quarter: 11,500 patients who stayed in hospital (called IPD), 1,51,000 outpatient visits (OPD), 19,400 day-care visits, 2,400 operational beds at 59% occupancy.
The company has been leaving government patients on purpose. Government-paid Panchakarma was ₹117 crore in FY25. It fell to ₹35 crore in FY26 and ₹5 crore in the June 2026 quarter. Government bodies pay slowly, so the company chose cash patients instead.
How big is the market?
Estimates for Ayurveda differ a lot. They depend on what each report counts.
Source What it measures Size Growth ------------ Mordor Intelligence (July 2026) India AYUSH and alternative medicine USD 24.87 billion (2025) to USD 36.62 billion (2031). Ayurveda is 71% of it. 6.7% a year IMARC Group India Ayurvedic products ₹875.9 billion (2024) to ₹3,605 billion (2033) 16.2% a year
Different reports give very different growth rates because they measure different parts of the Ayurveda and AYUSH market. Neither figure is the market for Jeena Sikho's own mix of hospitals, treatments and products. For hospitals, the company points out that India has about 19 lakh hospital beds in all. It runs about 2,400 operational beds, a very small share.
The numbers
₹ crore FY23 FY24 FY25 FY26 --------------- Revenue 204 324 469 801 Operating profit 46 93 141 351 Operating margin 23% 29% 30% 44% Net profit 34 69 80 222
FY25 profit was first reported as ₹90.7 crore. It now shows as about ₹80 crore after a change in accounting rules, which matches the 177% growth the company quotes for FY26. The promise table below uses the ₹90.7 crore that was reported at the time.
Recent quarters:
₹ crore Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 ------------------ Revenue 174 190 222 216 224 Operating margin 45% 48% 45% 36% 41% Net profit 51 59 67 45 66
Operating margin is the share of revenue left after running costs. Two cautions on the June 2026 quarter: - About ₹7 to 7.5 crore of the quarter's profit was a one-time gain (a ₹5 crore gain on warrants it holds in another company, and ₹2.5 crore of capital gain), as the CFO confirmed. Management says profit without it is about ₹56 to 58 crore, against ₹65.7 crore reported. - Revenue rose 29% from a year ago, but operating profit rose only 17%. Margins fell from 45% to 41% as advertising spending went up by about ₹4 crore.
Did management keep its promises?
Management gives targets freely on calls, so this check matters most. Here is what it said and what happened.
Said when What management said What happened Result ------------ May 2024 FY25 revenue about ₹450 crore, if occupancy reached 55% ₹469 crore Met May 2024 Profit margin of about 25% in FY25 About 19% (₹90.7 crore as first reported, on ₹469 crore) Missed May 2024 Add about 500 beds in FY25, to about 1,800 2,173 beds at March 2025 Beaten Sep 2024 (as an analyst quoted it) FY25 profit of ₹100 crore ₹90.7 crore Missed by 9% May 2025 FY26 revenue at least ₹720 crore ₹801 crore Beaten by 11% May 2025 FY26 profit of ₹130 to 140 crore, margin 23 to 25% ₹222 crore, margin 28% Beaten May 2025 More than 3,000 beds by 31 March 2026 About 2,300 operational beds (June 2026 call) Missed June 2026 3,000 operational beds "in the next 3 to 4 months" 2,400 beds in August 2026 Not met yet June 2026 30% yearly growth 29% in the June 2026 quarter Consistent so far
The pattern is clear: management exceeded its FY26 revenue and profit targets, but it has repeatedly fallen short of its bed-count targets. In FY25 it hit revenue but missed profit. Bed counts keep slipping while revenue grows, so occupancy stays at about 59%.
Are margins and capacity stable?
Margins rose sharply, then slipped. Operating margin went from 23% in FY23 to 44% in FY26, then to 36% and 41% in the last two quarters. Management says the products business (about 85% gross margin) and fewer low-paying government patients lifted it. It targets margins of 40% or more.
Capacity grows slowly. - Operational beds: 2,173 (March 2025), about 2,300 (June 2026), 2,400 (August 2026). Occupancy is 59%. - The number of hospital patients grew 33% in a year, but services revenue has remained between ₹95 and 105 crore for six quarters. The company is taking in more cheaper cases, such as poor patients at ₹4,000 to 6,000 a stay. So more patients do not yet mean proportionately more income. - Some projects were postponed. A new Lucknow hospital and an Ayodhya day-care clinic were put off on 9 September 2026 without a reason. The Panvel centre is stuck at 49 beds (target 250) while it waits for fire and pollution approvals.
Outlook and guidance (management's own forward-looking statements)
These are management's targets, not facts and not promises.
- Revenue: ₹3,000 crore in about 3 years, "before the fifth year" at the latest, with growth of about 30% a year. The MD says: "My target is the same, ₹3,000 crore of turnover, ₹1,000 crore of profit." - Profit: management said it expects profit in four years to be four to five times current profit (June 2026 call). Profit margin of 27 to 30%, operating margin of 40% or more. - Beds: 3,000 to 3,500 operational beds in FY27. 7,000 to 10,000 beds in 3 to 5 years, with 75 to 80% occupancy. - New models: - A luxury wellness centre in Manali called Jeena Sikho Premium. The company leases 35 or more of 108 rooms and 22 villas. It targets 50% occupancy in year 1, a room price of ₹32,000 to 35,000 and a 35 to 40% operating margin. The lease runs three years and can be renewed twice. The launch is due in September to October 2026 (delayed one month). - Three or four more such centres, with four operators already in talks. - A new chain of day-care centres. - Two or three more medicine-distribution partners, like Entero. - Government patients: management said its application to join Ayushman Bharat, the central government's health-cover scheme, has been approved at the Prime Minister's Office level. Rates are not final. Management expects 2 to 6 months. Until then it will take poor patients at ₹4,000 to 6,000 a stay on 500 beds. - Other: advertising budget up 25%. Recurring other income of ₹4 to 5 crore a quarter. July 2026 was the highest-ever month for revenue and admissions, and August was tracking ahead.
The point to remember Jeena Sikho beats its profit targets and misses its bed targets. Judge it by cash profit and occupancy, not by the target headline.
Cash and debt: a strength
₹ crore FY24 FY25 FY26 ------------ Net worth (equity plus reserves) 192 256 468 Borrowings incl. leases 1 117 127 Operating cash flow 37 84 262 Debtor days 46 66 32 Interest cost 0 11 14
Cash flow from operations of ₹262 crore in FY26 is about 75% of operating profit and about 1.2 times net profit. That is a healthy conversion. Debtor days (how many days customers take to pay) fell from 66 to 32 as the company left government patients.
The ₹117 to 127 crore of "borrowings incl. leases" in the table, as screener.in counts them, appears to be mostly lease liabilities, which is rent owed on leased hospital buildings. The FY25 standalone annual report shows only ₹10.7 crore of loans, and ₹10 crore of that came from directors. So bank-style debt looks small. Counting leases, debt is about 0.27 times net worth. In the same year, fixed assets as screener counts them (including rights to leased buildings) grew from ₹67 crore to ₹253 crore, and the company paid ₹70 crore in cash for Oregano Life Company (October 2024). Management quoted cash and bank balances of ₹108 crore at March 2026. The company pays out about 25% of profit as dividend.
Who runs it
It is a family-run board.
Name Age Role Background ------------ Manish Grover 51 Managing director since August 2021 (director since May 2017) B.Com and an honorary doctorate in Ayurveda and naturopathy. 29 years' experience (FY25 annual report). Founded the God Grace Foundation in 2009. Pay in FY25: ₹2.4 crore Bhavna Grover 49 Whole-time director B.A. 23 years' experience. Pay in FY25: ₹1.8 crore Shreya Grover 24 Whole-time director Daughter of the above. BA Hons and LLB. On the board since 2021, an executive since 2025. Two years' experience
(Ages from the FY25 annual report, the latest one I could read, plus a year for Manish Grover.)
- The board approved five-year re-appointments for Manish and Bhavna Grover from 25 August 2026, subject to the shareholders' vote at the 28 September meeting. - On 15 July 2026 the board added two whole-time directors (Ankush Kaushal and Dr Ish Sharma) and two independent directors. It also replaced its company secretary. Two resignations of directors or senior managers were filed the same day. I could not read their details. - A relative of a director is the IT head. The annual report also lists sales and purchases of ₹5.6 crore with Shuddhi Lifecare Private Limited, a related party. - A tax authority (the Chandigarh CGST office) took action against the company in February 2025. I did not read that filing, so check it.
Promoter holding: 63.6% in June 2026. It was 67.9% in March 2024, a fall of 4.3 points. Exchange data shows Manish Grover selling about 10 lakh shares in December 2024.
Recent buying: Bhavna Grover bought 35,000 shares on 28 September 2026 and 25,000 on 29 September in the open market. At about ₹480 a share, that is about ₹2.9 crore, close to the 52-week low.
Who else owns the stock
Quarter Promoters Foreign investors Domestic institutions Shareholders --------------- Mar 2024 67.9% 0.3% 0.0% 2,721 Mar 2025 63.5% 6.0% 0.2% 5,967 Sep 2025 63.6% 6.6% 0.2% 16,362 Mar 2026 63.6% 6.2% 0.5% 25,905 Jun 2026 63.6% 4.8% 0.4% 43,413
Foreign holding peaked at 6.6% in September 2025 and fell to 4.8% by June 2026. That fall came during the share price decline, and some market sites cite foreign selling as a reason. A falling percentage does not by itself prove selling. No mutual fund is disclosed as a large holder. Domestic institutions hold only 0.4%. Exchange bulk-deal data also shows large older trades, including Stallion Asset Private Limited buying about ₹31 crore of shares in February 2024 and a purchase by the Sixteenth Street Asian Gems Fund in 2024. Analysts from Nuvama and others ask questions on the calls, but I found no recent large fund purchase.
The stock fell about 20% to ₹492 on 1 June 2026, after the March 2026 quarter results. Profit that quarter was ₹45 crore, against ₹67 crore in the quarter before, and the margin fell from 45% to 36%.
Fundraising and investments
The company has not sold new shares since its 2022 IPO, as far as I could find. It has: - Invested in Chandan Healthcare. In October 2025 it agreed to subscribe to up to 18 lakh warrants (rights to buy shares later at a fixed price) at ₹234 each, about ₹42 crore, with 25% paid up front. It also made Chandan the exclusive diagnostics partner for its hospitals and clinics. - Bought Oregano Life Company for ₹70 crore in cash (October 2024). - Debt: bank-style debt looks small. Screener shows ₹127 crore of "borrowings" at March 2026, mostly leases. - Plans an employee share scheme. BSE approved the listing of up to 6,50,000 new shares (about 0.5%) under its 2024 scheme on 23 September 2026. Approval to list is not the same as shares being issued.
What to check before buying
- Beds against targets. Does it reach 3,000 operational beds, and does occupancy rise above 59%? - Margins. Are they holding near 40% after the added advertising, or are they falling toward 36%? - Profit without one-offs. Look at operating profit, not total profit. - Government cover. Does the Ayushman deal finalise, and at what rates? - Family control. The promoter family holds the top posts. Promoter stake has fallen 4.3 points in two and a half years. - Foreign holding. It fell at three quarter-ends in a row. - New models. The Manali luxury centre and the medicine-store channel are untested. - Regulation. Ayurveda advertising is under official scrutiny in India. I found no specific action on this company's advertising, but I did find the tax-authority action noted above.
Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.
Sources
- https://nsearchives.nseindia.com/corporate/JEENASIKHO14082026162330IntimationTranscript-Sign.pdf (Q1 FY27 call transcript) - https://nsearchives.nseindia.com/corporate/JEENASIKHO08062026163629IntimationTranscript.pdf (Q4 FY26 call transcript) - https://nsearchives.nseindia.com/corporate/JEENASIKHO26052025175716IntimationTranscript.pdf (Q4 FY25 call transcript) - https://nsearchives.nseindia.com/corporate/JSLL18112024192106TranscriptCallFinal.pdf (H1 FY25 call transcript) - https://nsearchives.nseindia.com/corporate/JSLL21052024191457transcriptconcallfinal.pdf (FY24 call transcript) - https://nsearchives.nseindia.com/annualreports/AR28319JSLL20242025A1346914303092025183539.pdf (annual report FY25) - https://nsearchives.nseindia.com/corporate/JEENASIKHO30052026185403OutcomeofBMFinal-Sign.pdf (board meeting outcome, dividend) - https://nsearchives.nseindia.com/corporate/JEENASIKHO29092026131925IntimationBhavnaGroversigned.pdf and https://nsearchives.nseindia.com/corporate/JEENASIKHO30092026131005IntimationBhavnaGrover30092026-Sign.pdf (promoter purchases) - https://www.nseindia.com/get-quote/equity/JSLL/Jeena-Sikho-Lifecare-Limited (company announcements list, May to October 2026) - https://www.theweek.in/wire-updates/business/2025/10/14/dcm78-biz-chandan-healthcare.html (Chandan Healthcare fundraise and partnership) - https://www.mordorintelligence.com/industry-reports/ayush-and-alternative-medicine-industry-in-india (market size) - https://imarcgroup.com/ayurvedic-products-market-in-india (market size) - https://www.kalkine.co.in/article/news/why-did-jeena-sikho-lifecare-shares-hit-the-lower-circuit-despite-profitable-results (June 2026 share price fall)